Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
324.3
% (year-on-year change in revenue for the fiscal year ended December 2025)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateNet SalesNot disclosed → ¥278 million
Operating profitNot disclosed → △ 1,081
Only the target level is shown because the current level for comparison was not provided.Investment amount by sectorField Growth Investment / Amount Not disclosed
Key initiatives
01Launch of regenerative medicine products and commercialization of the development pipeline
02Strengthening the research and development structure for the commercialization of cell products as a development company, and the management structure as a listed company
03Expanding the development pipeline and pursuing global expansion to achieve rapid growth after product launches
04Strengthening each business area
05Establishing a manufacturing and marketing structure
06Diversifying the earnings structure and expanding the partnership strategy
07Focusing on DX/AI and automated equipment development in preparation for commercial production
Plan assumptionsThe regenerative medicine market is expected to reach ¥53 trillion globally and approximately ¥2 trillion domestically by 2050., The 3D bioprinting market is forecast to reach approximately US$8.3 billion in 2030., Revenue is expected to begin growing following the launch of regenerative medicine products, with the effects of investment emerging after launch and earnings becoming more stable.
Non-financial targetsIndicator name Start of an investigator-initiated clinical trial for allogeneic peripheral nerve regeneration / Target value Start / Timing January 2026, Indicator name Start of an investigator-initiated clinical trial for osteochondral regeneration / Target value Scheduled to start / Timing First half of 2026, Indicator name Approval for peripheral nerve regeneration / Target value Approval expected / Timing Around 2028
Size of the Target MarketMarket Global regenerative medicine market / Dimensions ¥53 trillion in 2050 / Source Prepared by the company based on the Ministry of Economy, Trade and Industry's Final Report of the Study Group on the Commercialization and Industrialization of Regenerative Medicine, Market Japan's regenerative medicine market / Dimensions Approximately ¥2 trillion in 2050 / Source Prepared by the company based on the Ministry of Economy, Trade and Industry's Final Report of the Study Group on the Commercialization and Industrialization of Regenerative Medicine, Market US artificial nerve sales / Dimensions Approximately ¥12.5 billion (estimated 2022 sales) / Source axogen HP, Market Japan artificial nerve sales / Dimensions Approximately ¥3–5 billion / Source Estimated based on the company's research, Market 3D bioprinting market / Dimensions Approximately US$8.3 billion in 2030 / Source Precedence Research
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Plan period | Starting fiscal year Fiscal year ending December 2025 / Final year Fiscal year ending December 2030 and beyond |
| Progress against the plan | Annual update |
| Sales Target | Not disclosed → ¥278 million |
| Operating profit target | Not disclosed → △ 1,081 |
| Investment amount by sector | Field Growth Investment / Amount Not disclosed |
| Non-financial targets | Indicator name Start of an investigator-initiated clinical trial for allogeneic peripheral nerve regeneration / Target value Start / Timing January 2026, Indicator name Start of an investigator-initiated clinical trial for osteochondral regeneration / Target value Scheduled to start / Timing First half of 2026, Indicator name Approval for peripheral nerve regeneration / Target value Approval expected / Timing Around 2028 |
| Plan assumptions | The regenerative medicine market is expected to reach ¥53 trillion globally and approximately ¥2 trillion domestically by 2050., The 3D bioprinting market is forecast to reach approximately US$8.3 billion in 2030., Revenue is expected to begin growing following the launch of regenerative medicine products, with the effects of investment emerging after launch and earnings becoming more stable. |
| Key initiatives | Launch of regenerative medicine products and commercialization of the development pipeline, Strengthening the research and development structure for the commercialization of cell products as a development company, and the management structure as a listed company, Expanding the development pipeline and pursuing global expansion to achieve rapid growth after product launches, Strengthening each business area, Establishing a manufacturing and marketing structure, Diversifying the earnings structure and expanding the partnership strategy, Focusing on DX/AI and automated equipment development in preparation for commercial production |
| Size of the Target Market | Market Global regenerative medicine market / Dimensions ¥53 trillion in 2050 / Source Prepared by the company based on the Ministry of Economy, Trade and Industry's Final Report of the Study Group on the Commercialization and Industrialization of Regenerative Medicine, Market Japan's regenerative medicine market / Dimensions Approximately ¥2 trillion in 2050 / Source Prepared by the company based on the Ministry of Economy, Trade and Industry's Final Report of the Study Group on the Commercialization and Industrialization of Regenerative Medicine, Market US artificial nerve sales / Dimensions Approximately ¥12.5 billion (estimated 2022 sales) / Source axogen HP, Market Japan artificial nerve sales / Dimensions Approximately ¥3–5 billion / Source Estimated based on the company's research, Market 3D bioprinting market / Dimensions Approximately US$8.3 billion in 2030 / Source Precedence Research |
| Publication date | March 2026 |
Items this document does not state (14)
Operating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planSegment targetResults under the previous planReason for revision or withdrawalRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that it will prioritize growth investment to ensure the successful development and commercialization of regenerative medicine products, with the effects of this investment expected to emerge after product launches and earnings then becoming more stable.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.